Current appliance of bortezomib in multiple myeloma treatment

Halina Urbanska-Ryś; Monika Ryś

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

9/2008
vol. 12

Send email

Copy url:

abstract:

Current appliance of bortezomib in multiple myeloma treatment

Halina Urbanska-Ryś

,

Monika Ryś

Współczesna Onkologia (2008) vol. 12; 9 (415–420)

Online publish date: 2009/01/05

View full text Get citation

Multiple myeloma (MM) still remains an incurable malignancy of the lymphoid system. The appliance of new drugs in the therapy of MM, including the proteasome inhibitor bortezomib, changes treatment results and prognosis. Bortezomib (VelcadeTM) is given routinely in the dose of 1.3 mg/m² on days 1, 4, 8, 11 of a 21-day cycle in relapsed and refractory MM, but the results of clinical trials suggest its efficacy in the induction phase of the treatment regardless of patient’s age. Bortezomib is effective in monotherapy, but its synergism with other drugs means that it is actually more effective when administered in combinations with dexamethasone, doxorubicin, liposomal, pegylated doxorubicin, cyclophosphamide, thalidomide and lenalidomide. Adverse events observed after bortezomib treatment are usually predictable and manageable. Polyneuropathy diagnosed in about 30% of patients treated with bortezomib imposes dose reduction to 1.0 and 0.7 mg/m² and is reversible in most patients after therapy completion.

keywords:

Current appliance of bortezomib in multiple myeloma treatment

Halina Urbanska-Ryś , Monika Ryś

multiple myeloma, bortezomib, combination regimens

Halina Urbanska-Ryś

,

Monika Ryś